BRAF and thyroid cancer: DSF/Cu enhances the sensitivity of BRAF-mutant thyroid cancer cells to PLX4032 by inhibiting HER3 and AKT in a ROS-dependent manner, thereby alleviating the feedback activation of the MAPK/ERK and PI3K/AKT pathways